Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Bone Health to Targeted Pharmacovigilance

The legacy of general health and science communication has long emphasized the importance of understanding how systemic factors influence localized conditions. In the context of bone health, public discourse has historically focused on broad preventive measures and the management of age-related skeletal changes. This foundational knowledge established a framework for recognizing that interventions intended to support one aspect of health may carry implications for other bodily systems. As clinical awareness evolved, attention shifted toward specific pharmaceutical exposures and their potential downstream effects. Within this progression, the transition from general bone health considerations to a more targeted inquiry becomes evident. The focus narrows to bisphosphonate therapy, particularly Fosamax, and its association with osteonecrosis of the jaw. This condition represents a convergence of dental and skeletal health, where routine oral procedures or spontaneous events may reveal underlying tissue vulnerability. The clinical evidence review of this relationship requires careful examination of exposure duration, dosage, and patient-specific risk factors. By moving from broad health education to a precise pharmacovigilance concern, the discussion now pivots to occupational exposure contexts—where healthcare professionals, dental practitioners, and patients alike must navigate the balance between therapeutic benefit and adverse outcomes. This transition underscores the necessity of integrating legacy health principles with emerging clinical observations.

Bridging General Principles to Fosamax-Specific Risks

Building on the foundational understanding of systemic influences on localized conditions, the clinical evidence now directs attention to the specific relationship between Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Risk Factors and Mechanistic Pathways

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current research suggests that bisphosphonates, including alendronate, alter bone remodeling by inhibiting osteoclast activity. This suppression of bone turnover may impair the jawbone's ability to repair microdamage and respond to local stressors such as infection or dental procedures. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique biology of the jawbone, which may make it particularly susceptible to the effects of bisphosphonate therapy.

Clinical Presentation and Diagnosis

Clinical presentation of ONJ typically involves exposed bone in the maxillofacial region that persists for more than eight weeks. Diagnosis is based on clinical examination and imaging, with exclusion of metastatic disease or other causes. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Label Warnings and Causation Considerations

From a risk perspective, the adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, the label notes that the optimal duration of use has not been determined, and for patients at low risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This guidance reflects an awareness of the potential for cumulative risk with prolonged exposure. Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ. The timeline between exposure and documented harm can range from days to months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ can also occur spontaneously, and many cases are associated with additional risk factors such as dental procedures or local infection. Therefore, while Fosamax is a recognized risk factor, causation in individual cases may require careful evaluation of the patient's overall clinical picture, including the presence of other predisposing conditions. The label's warning that ONJ has been reported in patients taking bisphosphonates, including Fosamax, supports a causal association, but the condition is not exclusive to bisphosphonate use.

Summary and Clinical Implications

In summary, Fosamax is an effective medication for osteoporosis and other bone conditions, but its use carries a risk of ONJ, particularly in patients with additional risk factors. The prescribing information provides warnings and management recommendations, including consideration of drug discontinuation for low-risk patients after several years of use. Patients who develop ONJ while on Fosamax should be evaluated for other contributing factors, and discontinuation of the drug may lead to symptom relief in most cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. The prescribing information includes a specific warning about this risk, noting that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while on Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate exposure.

How is ONJ diagnosed and what is the typical timeline after starting Fosamax?

ONJ is diagnosed based on clinical examination and imaging, showing exposed bone in the maxillofacial region persisting for more than eight weeks. The time to onset of symptoms after starting Fosamax can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.